

Department of Pharmaceuticals

1. National Institutes of Pharmaceutical Education and Research (NIPERs) (CS)

Financial outlay (in cr. ₹) FY 2025-26	Outputs 2025-26			Outcomes 2025-26		
	Outputs	Indicator(s)	Target 2025-26	Outputs	Indicator(s)	Target 2025-26
200.07	1. Construction of regular campus for NIPERs- Hyderabad, Raebareli, Hajipur and Kolkata	1.1 Construction of regular campus (% of progress) (Raebareli)	100	1. NIPERs with their own building and campus	1.1 NIPERs functional from their own campus	4
		1.2 Construction of regular campus (% of progress) (Hyderabad).	75			
		1.3 Construction of regular campus (% of progress) (Kolkata)	75			
		1.4 Construction of regular campus (% of progress) (Hajipur)	75			
	2. Number of students trained in pharmaceutical education for industry	2.1 Intake of students for Masters level courses in NIPERs (in numbers) 2.2 Number of short-term technical courses completed at NIPERs	1,000 50	2. Increase in number of experts and professionals for the industry 3. Research publications and patents	2.1 Percentage of students getting placements 3.1 Number of research papers published in high-impact journals	90 250

Financial outlay (in cr. ₹) FY 2025-26	Outputs 2025-26			Outcomes 2025-26		
	Outputs	Indicator(s)	Target 2025-26	Outputs	Indicator(s)	Target 2025-26
		2.3 Number of students who completed PhD course from NIPERs	50		3.2 Number of patents filed through research at NIPERs	25

2. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)

Financial outlay (in cr. ₹) FY 2025-26	Outputs 2025-26			Outcomes 2025-26		
	Outputs	Indicator(s)	Targets 2025-26	Outcomes	Indicator(s)	Targets 2025-26
	1. Operationalise Jan Aushadhi Kendras in the country	1.1 Number of new Janaushadhi Kendras in the country	5,000	1. Enhanced coverage	1.1 Percentage of districts covered in India	100%
353.50	2. Enhanced sales turnover of medicines under PMBJP	2.1 Annual increase in sales turnover of medicines (in cr. ₹)	500	2. Reduction of out-of-pocket expenditure on medicines	2.1 Estimated savings to consumers (in cr. ₹)	2,000
	3. Ensure stocking mandate for commonly used medicines	3.1 Number of medicines under minimum stocking mandate at Jan Aushadhi Kendras	200	3. Increase in availability of medicines at PMBJKs	3.1 PMBJK stores where minimum stocking mandate is to be achieved (in percentage)	60

3. Scheme for Strengthening of Medical Device Industry

Financial outlay (in cr. ₹) FY 2025-26	Outputs 2025-26			Outcomes 2025-26		
	Outputs	Indicator(s)	Targets 2025-26	Outcomes	Indicator(s)	Targets 2025-26
360.00	a. Common Facilities for Medical Devices Clusters					
	1. Creation of Common Facility / Testing Labs	1.1 Approval of Common Facilities Testing / Facilities projects in FY2025-26	10	1. Completion of AMD-CF projects in FY2025-26	1.1 Industries benefitted from the Scheme	10
	b. Capacity Building and Skill Development for Medical Devices					
	1. Training Infrastructure upgradation and Capacity Building and Skill Development course in medical devices.	1.1 Students admitted to Master's level courses in selected institutes (in number)	200	1. Increased availability of skilled manpower in medical device sector and training infrastructure	1.1 Number of institutes with upgraded training infrastructure	5
		1.2 Certificate courses organised for medical device technicians (in number)	10		1.2 Technicians successfully upgraded through certificate courses (in number)	100
	c. Medical Device Promotion Scheme					
	1. Organisation of conferences / seminars and workshops relevant to growth of pharmaceutical industry	1.1 Number of conferences, seminars and workshops organised	5	1. Enhanced awareness and sensitisation of pharma industry on issues relevant to the industry	1.1 Participation in conferences, seminars and workshops organised	100

Financial outlay (in cr. ₹) FY 2025-26	Outputs 2025-26			Outcomes 2025-26		
	Outputs	Indicator(s)	Targets 2025-26	Outcomes	Indicator(s)	Targets 2025-26
	2. Conduct studies on MediTech industry under the scheme	2.1 Number of studies undertaken	2	2. Study Reports completed on meditech industries	2.1 Number of studies completed and reports finalised	2
	d. Marginal Investment Scheme for Reducing Import Dependence					
	1. Production of key raw material used in the medical device industry will be started	1.1 Approval of applicants for production of raw materials used in manufacturing of medical devices	10	1. Increase in number of units producing key raw material used in medical devices	1.1 Number of projects completed under the scheme	5
	e. Medical Device Clinical Studies Support Scheme					
	1. Increase in clinical studies conducted by manufacturers of medical devices	1.1 Number of clinical studies approved	10	1. Promote manufacturing of quality production with better efficacy and safety	1.1 Number of clinical studies completed	5

4. Consumer Awareness, Publicity and Price Monitoring (CS)

Financial outlay (in cr. ₹) FY 2025-26	Outputs 2025-26			Outcomes 2025-26		
	Outputs	Indicator(s)	Target 2025-26	Outputs	Indicator(s)	Target 2025-26
	1. Awareness creation through publicity and advertisement	1.1 Number of publicity campaigns through hoardings, LED screens, social media, etc.	2	1. Improving knowledge and awareness about availability of medicines, ceiling prices of medicines fixed by the	1.1 Average number of unique views per digital campaign	500

Financial outlay (in cr. ₹) FY 2025-26	Outputs 2025-26			Outcomes 2025-26		
	Outputs	Indicator(s)	Target 2025-26	Outputs	Indicator(s)	Target 2025-26
		1.2 Number of Seminars, webinars, workshops and conferences organised.	2	Government, precautions to be taken while purchasing medicines and about functioning of NPPA 2. Monitoring prices of drugs, pursue overcharge cases, address shortages and generate public awareness about affordable drugs.	1.2 Number of individuals/ stakeholders participating in seminars, webinars and conferences organised. 2.1 Percentage of complaints acted upon / addressed by NPPA for violation of pricing mechanism	500 100

5. Promotion of Research and Innovation in Pharma-Med Tech (PRIP) (CS)

Financial outlay (in cr. ₹) FY 2025-26	Outputs 2025-26			Outcomes 2025-26		
	Outputs	Indicator(s)	Targets 2025-26	Outcomes	Indicator(s)	Targets 2025-26
	1. Setting up of Centre of Excellence (CoE) under component A 2. Selection of Companies / Start-ups under Component-B	1.1 Recruitment of personnel for running the CoE by the respective NIPERs ¹ 2.1 Selection of eligible companies under Component B (in number)	7 20	1. Component-A - Strengthening the R&D infrastructure and activities at NIPERs 2. Component-B - Promotion of private initiative in R&D in Pharma Meditech sector in six priority areas.	1.1 Release of second tranche of funds to the NIPERs for establishing of CoE 2.1 Release of the first tranche of funds to the selected companies under component B.	7 20

¹ NIPER: National Institutes of Pharmaceutical Education and Research